Qingfei Paidu Decoction (清肺排毒汤) Combined with Western Medicine Routine Treatment for Coronavirus Disease 2019 with Hypertension: A Retrospective Study of 119 Cases
|更新时间:2021-10-15
|
Qingfei Paidu Decoction (清肺排毒汤) Combined with Western Medicine Routine Treatment for Coronavirus Disease 2019 with Hypertension: A Retrospective Study of 119 Cases
Journal of Traditional Chinese MedicineVol. 62, Issue 20, Pages: 1795-1800(2021)
LI Huizhen,WANG Jingya,GUO Yuna,et al.Qingfei Paidu Decoction (清肺排毒汤) Combined with Western Medicine Routine Treatment for Coronavirus Disease 2019 with Hypertension: A Retrospective Study of 119 Cases[J].Journal of Traditional Chinese Medicine,2021,62(20):1795-1800.
LI Huizhen,WANG Jingya,GUO Yuna,et al.Qingfei Paidu Decoction (清肺排毒汤) Combined with Western Medicine Routine Treatment for Coronavirus Disease 2019 with Hypertension: A Retrospective Study of 119 Cases[J].Journal of Traditional Chinese Medicine,2021,62(20):1795-1800.DOI: 10.13288/j.11-2166/r.2021.20.009.
Qingfei Paidu Decoction (清肺排毒汤) Combined with Western Medicine Routine Treatment for Coronavirus Disease 2019 with Hypertension: A Retrospective Study of 119 Cases
(清肺排毒汤) combined with western medicine for treatment of coronavirus disease 2019 (COVID-19) with hypertension.
Methods
2
Data of confirmed COVID-19 cases with hypertension who were treated by
Qingfei Paidu Decoction
for
at least two courses (6 days)
was retrospectively collected from 27 medical institutions in 8 provinces (cities) from January 21 to March 4, 2020. Patients were divided into elderly group (≥60 years old) and non-elderly group (<60 years old), and were compared on the improvement of main clinical symptoms, the time to negative conversion of nucleic acid test result, the time of hospitalization, the improvement of lung lesions, and adverse reactions.
Results
2
A total of 119 patients were included, with a median age of 57, ranging from 22 to 87 years old. There were 68 patients in non-elderly group and 51 patients in elderly group. The clinical symptoms were mainly cough (55.5%), fever (47.9%), dry cough (31.9%), fatigue (26.1%), asthma (12.6%), and anorexia (16.0%); 74.7% of the 99 cases with abnormal lung imaging results showed absorption of lung lesions; 99.2% (118/119) patients were cured and discharged. The median time of hospital stay was 16 days, with significant longer days of the elderly group (20 days) than that of the non-elderly group (16 days,
P
<0.05). In terms of time to negative conversion of nucleic acid test result, time to relief of fever, fatigue, cough, dry cough, anorexia, and asthma, lung lesions absorption rate, there were no statistically significant differences between elderly and non-elderly group (
P
>0.05). No serious adverse events occurred in all patients during hospitalization.
Conclusion
2
Qingfei Paidu Decoction
can effectively improve the clinical symptoms of patients of COVID-19 with hypertension, and is safe.
MA Y , ZHU DS , CHEN RB , et al . Association of overlapped and un-overlapped comorbidities with COVID-19 severity and treatment outcomes: a retrospective cohort study from nine provinces in China [J]. Biomed Environ Sci , 2020 , 33 ( 12 ): 893 - 905 .
SALAZAR M , BAROCHINER J , ESPECHE W , et al . COVID-19 and its relationship with hypertension and cardiovascular disease [J]. Hipertens Riesgo Vasc , 2020 , 37 ( 4 ): 176 - 180 .
TRUMP S , LUKASSEN S , ANKER MS , et al . Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19 [J]. Nat Biotechnol , 2020 : 1 - 12 . doi: 10.1038/s41587-020-00796-1 http://dx.doi.org/10.1038/s41587-020-00796-1 .
ZHANG P , ZHU L , CAI J , et al . Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19 [J]. Circ Res , 2020 , 126 ( 12 ): 1671 - 1681 .
SHI N , LIU B , LIANG N , et al . Association between early treatment with Qingfei Paidu decoction and favorable clinical outcomes in patients with COVID-19: A retrospective multicenter cohort study [J]. Pharmacol Res , 2020 : 105290 . doi: 10.1016/j.phrs.2020.10 5290 http://dx.doi.org/10.1016/j.phrs.2020.105290 .
XU X , CHEN P , WANG J , et al . Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission [J]. Sci China Life Sci , 2020 , 63 ( 3 ): 457 - 460 .
CAO P , WU S , WU T , et al . The important role of polysaccharides from a traditional Chinese medicine-Lung Cleansing and Detoxifying Decoction against the COVID-19 pandemic [J]. Carbohydr Polym , 2020 , 240 : 116346 . doi: 10.1016/j.carbpol. 2020.116346 http://dx.doi.org/10.1016/j.carbpol.2020.116346 .
Qingfei Paidu Decoction (清肺排毒汤) Combined with Conventional Therapy for 50 Severe Cases of Coronavirus Disease 2019 (COVID-19): A Retrospective Study
Qingfei Paidu Decoction (清肺排毒汤) Combined with Western Routine Treatment for Elderly Patients with Coronavirus Disease 2019: A Retrospective Study
连花清瘟颗粒联合西药常规疗法治疗新型冠状病毒肺炎疑似病例63例临床观察
Effect of Traditional Chinese Medicine Therapy on Immune Reconstitution in Children after Hematopoietic Stem Cell Transplantation:A Retrospective Real-World Study
Real-World Effects Evaluation of the Strengthening Spleen,Tonifying the Kidney,and Detoxifying Method in the Treatment of Advanced Colorectal Cancer:A Multi-Center,Retrospective Cohort Study
Related Author
Fang WANG
Yang GUO
Liwen JIAO
Xinyang ZHANG
Ning LIANG
Li GUAN
Xingyu ZONG
Xiangjia LUAN
Related Institution
Community Health Service Management Center, Dongcheng District
Institute of Basic Research in clinical Medicine,China Academy of Chinese Medical Sciences
The First Hospital of Suihua City
Infectious Disease Hospital of Heilongjiang Province
Institute of Information on Traditional Chinese Medicine,China Academy of Chinese Medical Sciences